Brief: Timber Pharmaceuticals Receives European Orphan Designation For Autosomal Recessive Congenital Ichthyosis & Positive Comments On Pediatric Investigation Plan For Tmb-001 In Autosomal Recessive Ci & X-Linked Recessive Ichthyosis

Trex Wind-Down

25/10/2022 15:31

Oct 25 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS RECEIVES EUROPEAN ORPHAN
DESIGNATION FOR
AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS & POSITIVE COMMENTS ON
PEDIATRIC INVESTIGATION PLAN FOR TMB-001 IN AUTOSOMAL RECESSIVE
CI & X-LINKED RECESSIVE ICHTHYOSIS
    * TIMBER - PLANS TO SUBMIT ADDITIONAL APPLICATION FOR ORPHAN
DESIGNATION IN EUROPE FOR TMB-001 FOR TREATMENT OF X-LINKED
RECESSIVE ICHTHYOSIS

Source text for Eikon:  ID:nGNX33Bj7b 
Further company coverage:  TMBR.A 
 ((Reuters.Briefs@thomsonreuters.com;;))